Literature DB >> 10567816

ELISA-quantitation of phosphorylated tau protein in the Alzheimer's disease brain.

M Herrmann1, S Golombowski, K Kräuchi, P Frey, C Mourton-Gilles, C Hulette, C Rosenberg, F Müller-Spahn, C Hock.   

Abstract

A reliable, sensitive and specific sandwich ELISA for the quantitation of paired helical filament (PHF) tau in human brain was developed using well-defined monoclonal antibodies. We examined rapid-autopsy-derived brain tissue from 21 neuropathologically confirmed Alzheimer's disease (AD) patients and 14 nondemented controls, matched for age, sex and postmortem delay times. We demonstrated significant elevations of phosphorylated tau levels in the frontal and parietal cortex as well as in the hippocampus of AD patients as compared to the nondemented controls. No difference was observed in the cerebellum. Phosphorylated tau levels measured by ELISA were significantly correlated with the presence or absence of neurofibrillary tangles. Copyright 1999 S. Karger AG, Basel

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10567816     DOI： 10.1159/000008108

Source DB:  PubMed          Journal:  Eur Neurol        ISSN： 0014-3022            Impact factor:   1.710


  4 in total

1.  Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.

Authors:  Konrad Talbot; Hoau-Yan Wang; Hala Kazi; Li-Ying Han; Kalindi P Bakshi; Andres Stucky; Robert L Fuino; Krista R Kawaguchi; Andrew J Samoyedny; Robert S Wilson; Zoe Arvanitakis; Julie A Schneider; Bryan A Wolf; David A Bennett; John Q Trojanowski; Steven E Arnold
Journal:  J Clin Invest       Date:  2012-04       Impact factor: 14.808

2.  A new method to quantify tau pathologies with (11)C-PBB3 PET using reference tissue voxels extracted from brain cortical gray matter.

Authors:  Yasuyuki Kimura; Hironobu Endo; Masanori Ichise; Hitoshi Shimada; Chie Seki; Yoko Ikoma; Hitoshi Shinotoh; Makiko Yamada; Makoto Higuchi; Ming-Rong Zhang; Tetsuya Suhara
Journal:  EJNMMI Res       Date:  2016-03-12       Impact factor: 3.138

3.  Impact of TSPO Receptor Polymorphism on [18F]GE-180 Binding in Healthy Brain and Pseudo-Reference Regions of Neurooncological and Neurodegenerative Disorders.

Authors:  Franziska J Vettermann; Stefanie Harris; Julia Schmitt; Marcus Unterrainer; Simon Lindner; Boris-Stephan Rauchmann; Carla Palleis; Endy Weidinger; Leonie Beyer; Florian Eckenweber; Sebastian Schuster; Gloria Biechele; Christian Ferschmann; Vladimir M Milenkovic; Christian H Wetzel; Rainer Rupprecht; Daniel Janowitz; Katharina Buerger; Robert Perneczky; Günter U Höglinger; Johannes Levin; Christian Haass; Joerg C Tonn; Maximilian Niyazi; Peter Bartenstein; Nathalie L Albert; Matthias Brendel
Journal:  Life (Basel)       Date:  2021-05-26

4.  Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.

Authors:  Gordon K Wilcock; Serge Gauthier; Giovanni B Frisoni; Jianping Jia; Jiri H Hardlund; Hans J Moebius; Peter Bentham; Karin A Kook; Bjoern O Schelter; Damon J Wischik; Charles S Davis; Roger T Staff; Vesna Vuksanovic; Trevor Ahearn; Luc Bracoud; Kohkan Shamsi; Ken Marek; John Seibyl; Gernot Riedel; John M D Storey; Charles R Harrington; Claude M Wischik
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.